THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Thursday, March 12, 2026

COMPOUND WATCH

Compounded Tirzepatide (w/ additives) — ⚠️ ACTIVE WARNING Semaglutide (compounded) — Hims/Novo deal pressure holding BPC-157 — Phase 2 RCT recruiting (since Feb 2) [Phase 2] Retatrutide — Phase 3 recruiting (since Jan 24) [Phase 3] RFK Category 2 reclassification — Day 13 post-Rogan. Still nothing.

Eli Lilly dropped a grenade on the compounded GLP-1 market today. The company claims it found "significant levels of an impurity" — a chemical reaction byproduct — in compounded tirzepatide products containing B12, glycine, pyridoxine, niacinamide, carnitine, or other personalized additives. Lilly formally asked the FDA to recall all compounded tirzepatide with these additives. The FDA has not acted. This is a manufacturer-initiated warning, not an enforcement order — but if you're on a tirzepatide-B12 compound right now, that's the most important sentence in today's issue.

The mechanism matters: this isn't a sterility claim. Lilly is alleging a chemical reaction between tirzepatide and the additive creates a novel impurity with "unknown risks." That framing is deliberate — designed to scare patients and pressure the FDA simultaneously. Whether the impurity levels are clinically meaningful is unknown. Lilly hasn't published the underlying test data. Until they do, treat this as a motivated claim from a company that loses $200-500/month per patient to every compounder.

That said: the chemistry concern is not implausible. Peptide stability in combination formulations is genuinely complex, and most compounders don't run stability testing to know what's happening in the vial over 30-90 days.

If you're on tirzepatide-B12 or any combination formula: Ask your compounder what stability testing they've run on the specific formulation. "We use pharmaceutical-grade ingredients" is not an answer. If they can't produce stability data, here's the decision tree for the answer you're most likely to get: No stability data → switch to plain tirzepatide base compound (not named in today's warning) or price brand Zepbound now (list prices are, per Gizmodo, "now finally close to the prices for compounded versions"). Stopping the additive while continuing plain tirzepatide is the lowest-disruption option if your compounder can supply it. Switching to brand removes the formulation risk entirely but at higher cost.

VENDOR SIGNAL

No new Finnrick rating changes or Janoshik HPLC results confirmed today. Check finnrick.com directly before your next order.

The 15-20% rule: Across independent HPLC testing programs, roughly 15-20% of peptide supplier samples show meaningful discrepancies from their COA — wrong concentration, wrong compound, or both. If you haven't independently verified your current source, you're trusting a document the vendor produced about their own product. That's not verification.

Compounded tirzepatide + additives [Flagged] — Lilly's impurity claim applies specifically to combination formulations. Plain tirzepatide base compound is not named. Even a [Verified] compounder selling tirzepatide-B12 is now a sourcing risk on that specific formulation until this resolves.

Peptide Sciences wind-down — The Frier Levitt legal analysis (March 10) cited Peptide Sciences announcing it would wind down operations and discontinue research peptide sales — consistent with the broader enforcement pressure on "For Research Purposes Only" vendors. If they were your primary BPC-157 or TB-500 source, check their site directly before assuming supply is gone; no independent confirmation has appeared since March 10. For alternatives with current Finnrick verification, check finnrick.com directly — no new ratings confirmed today.

Gray-market enforcement trajectory — Justin Prochnow (Greenberg Traurig), writing in Supply Side Journal, explicitly states the FDA "will need to weigh in" on peptides marketed as "For Research Purposes Only" when that's not the actual use case. This is a senior regulatory attorney framing enforcement as near-term inevitability. Vendors operating under the research-use label are on borrowed time regardless of what RFK does.

Australian TGA parallel — The Aesthetic Medical Practitioner published a dedicated grey market scrutiny piece covering BPC-157, TB-500, GHK-Cu, retatrutide, Melanotan II, and Dihexa circulating in Australian online communities. The TGA is running the same playbook as the FDA. If your vendor ships internationally, this is a new customs variable.

No U.S. compounder pricing data available today — Finnrick/Janoshik grades reflect last known status.

TRIAL TRACKER

BPC-157 — Phase 2 RCT (NCT07437547) [Phase 2] — RECRUITING The compound injected by hundreds of thousands of people with zero published human RCTs finally has one underway. Recruiting since February 2, 2026; targets acute hamstring muscle strain repair. This doesn't validate the broader anecdotal use cases (gut healing, tendon regeneration, systemic injury) — it tests one specific indication. But it establishes a human safety and dosing baseline that has never existed. One complication: A University of Utah paper (Current Reviews in Musculoskeletal Medicine) raises a theoretical concern that BPC-157 could promote tumor cell growth — the same concern giving the FDA scientific cover to delay reclassification. The Phase 2 trial will generate the first human safety data that could either validate or dismiss this. See Regulatory Radar for the reclassification implications. Action: Bookmark NCT07437547. Interim safety data is the first signal that will move the evidence grade from [Anecdotal] toward something you can actually rely on.

Retatrutide — Phase 3 (NCT07357415) [Phase 3] — RECRUITING since Jan 24 Lilly's triple agonist (GLP-1/GIP/glucagon) in Phase 3 for obesity in non-diabetic patients. Phase 2 showed 24% weight loss at 48 weeks — the highest efficacy signal of any compound in this class, including tirzepatide. The gray market version circulating today has zero Phase 3 safety data. That's the trade-off you're making.

Survodutide — Phase 3 MASH (NCT06632444) [Phase 3] — RECRUITING Boehringer Ingelheim's GLP-1/glucagon dual agonist in two simultaneous Phase 3 MASH trials (LIVERAGE). MASH is the next major GLP-1 indication after obesity and T2D — and the next compounding demand category if approved. Watch LIVERAGE readouts as the next market-shaping event after orforglipron (PDUFA: April 10, 2026).

THE ODDS

Polymarket as of March 12, 2026. Volume = real money, real signal.

The signal that matters most today: Inflation above 3% in 2026 — 80% probability ($114,762 traded) This is the most direct macro input to your sourcing decisions right now. The chain: sustained inflation → more patients price-shopping → more gray-market sourcing, fewer compounder orders. It also means your $200-500/month compounder bill gets more expensive in real terms, and Chinese API costs (currently $2-5/vial at origin) face upward pressure through the supply chain. If you're planning to stock up on any compound, the cost-of-goods argument for doing it in Q2 rather than Q3 is real — though note this is a directional argument, not a guarantee.

US Recession by end of 2026 — 32% probability ($515,627 traded) Below the rough threshold where gray-market sourcing historically accelerates. Caveat: the 35-40% threshold is a rule of thumb based on consumer behavior patterns during 2008-2009 and COVID-era supply disruptions — not a hard rule; treat it as directional. Below 35%, the current spending pattern likely holds. Watch for drift above that level. If it crosses 40%: expect more patients migrating from 503A/503B compounders to research vendors, more QSC/SRY orders relative to domestic compounders.

No Fed rate cuts in 2026 — 23% probability ($1.84M traded) The largest volume signal in today's set. 77% probability of at least one cut means capital costs stay on a loosening trajectory — a marginal tailwind for 503B facilities carrying significant cleanroom and QC infrastructure costs. Not a primary driver, but relevant to compounder survival in a tightening enforcement environment.

Tariffs — Trump tariff dividend by March 31 — 2% probability ($135,479 traded) Near-zero on the dividend, but the structural tariff regime on Chinese goods remains active. A 25% tariff on Chinese goods could raise gray-market peptide costs 15-30% from current levels. No imminent trigger today.

SIGNAL VS. NOISE

SIGNAL: Lilly's tirzepatide-B12 impurity warning Real, with teeth, specific mechanism. A manufacturer formally requesting an FDA recall creates legal liability for compounders who continue selling flagged formulations. The underlying chemistry concern is scientifically legitimate even if Lilly's motives are commercial. Action: Ask your compounder for stability testing data on any combination tirzepatide formula. If they can't produce it, see the decision tree in Compound Watch above.

SIGNAL: BPC-157 Phase 2 RCT now recruiting First registered, recruiting Phase 2 human trial for BPC-157 in the compound's history. Doesn't validate your current use case — but begins generating human data. Complicated by the University of Utah tumor promotion concern (see Trial Tracker and Regulatory Radar). Action: Bookmark NCT07437547.

SIGNAL: FDA warning letter to Novo Nordisk for unreported semaglutide deaths The FDA issued a formal warning letter to Novo Nordisk (March 11) for failing to report two patient deaths (one not reported at all), one suicide (not yet reported), one suicidal ideation case (reported late), and one disabling stroke on liraglutide (rejected by Novo). The inspection covered January 13–February 7, 2025 — note the timeline: FDA inspected in early 2025 and issued the warning letter 13 months later. That lag is itself relevant context about how slowly FDA enforcement moves, even when violations are serious. Novo's regulatory credibility is now eroding simultaneously with its commercial position (stock near 52-week lows, REDEFINE 4 failure, Goldman/TD Cowen downgrades). This affects the Hims/Novo deal's long-term stability.

SIGNAL: GLP-1 weight regain — two studies, directionally consistent The Cambridge meta-analysis (48 studies, 3,236 participants) found patients regain 60% of lost weight within 1 year of stopping GLP-1s, with a 23-week weight-regain half-life and a predicted plateau at 75% of original weight loss. The Cleveland Clinic real-world study (~8,000 patients) found 55% gained weight in the year after stopping — but 45% kept losing or stayed the same, partially because many restarted medication. The real-world picture is more complex than the Cambridge RCT-based figure when re-treatment is available. Critical buried finding in both datasets: 40-60% of weight lost during GLP-1 treatment was lean mass (muscle), not fat. That's not a side effect footnote. That's a fundamental question about what these drugs are doing to body composition — and the direct rationale for stacking a GLP-1 with BPC-157 [Anecdotal] or TB-500 [Anecdotal].

SIGNAL: GLP-1 addiction — VA/BMJ study, quantified The VA/BMJ study (606,434 veterans) found GLP-1s prevented roughly 7 cases of SUD and 12 hospitalizations, overdoses, or deaths per 1,000 patients — across all major substances, not just one. That's the quantified signal. The mechanism is mesolimbic reward circuit modulation, not substance-specific targeting. Dr. Anna Lembke (Stanford) correctly notes these drugs don't work the same for everyone and carry GI, pancreatitis, and kidney risks. The signal is real. The "Ozempic cures addiction" framing circulating on social media is noise.

NOISE: RFK Jr. "Hot Peptide Summer" — GQ mainstream feature GQ's piece is well-written and will flood r/peptides with new users who've never reconstituted a vial. The regulatory status is unchanged: RFK promised action "in a couple of weeks" on Joe Rogan (February 27). It is now March 12 — Day 13. No Federal Register notice. No formal FDA rule. No HHS response to press inquiries. The Supply Side Journal analysis frames federal action as "posturing and floating trial balloons." Even if reclassification is announced tomorrow, Dr. Duncan (quoted in GQ) notes manufacturing scale-up takes "at least weeks, if not months." Don't buy inventory based on a podcast promise.

REGULATORY RADAR

RFK reclassification clock: Day 13, still nothing The "couple of weeks" window RFK cited on Rogan has elapsed. No Federal Register notice. No formal FDA rule. The GQ mainstream feature is now amplifying consumer expectations dramatically ahead of any actual regulatory action — which creates a specific risk: gray-market vendors will use the coverage to market aggressively to buyers who don't understand that "RFK said it" and "FDA did it" are completely different things. Complicating factor: the University of Utah paper (Current Reviews in Musculoskeletal Medicine) raises a theoretical BPC-157 tumor promotion concern — giving the FDA legitimate scientific cover to delay or narrow any reclassification. If and when reclassification happens, same-week compounder availability is not realistic.

The three-front GLP-1 compounding squeeze — confirmed and escalating Three simultaneous pressure vectors as of today: 1. Novo/Hims truce (March 9) — largest telehealth compounding pipeline redirected to brand product 2. Lilly impurity warning + recall request (March 12) — tirzepatide combination formulas under active manufacturer scrutiny 3. FDA 30 warning letters (March 3) — batch enforcement against compounders ongoing

The 503A/503B compounding window for GLP-1s is closing. The question is no longer if but how fast. Start pricing brand alternatives now. The cost gap is narrowing.

Orforglipron PDUFA: April 10, 2026 Lilly's oral non-peptide GLP-1 agonist. Approval = first oral GLP-1 requiring no injection or refrigeration — structural disruption to the entire injectable compounding market. Mark the date.

WHAT TO WATCH

Now: Call your compounder. Ask specifically whether your tirzepatide formula contains B12, glycine, pyridoxine, niacinamide, carnitine, or other additives. If yes, ask for stability testing data on that specific formulation. If they can't produce it: switch to plain tirzepatide base compound (not named in today's warning), or price brand Zepbound as a fallback.

Now: Check finnrick.com before your next research peptide order. No new ratings confirmed today — but the Peptide Sciences wind-down (if confirmed) removes one sourcing option without warning.

April 10, 2026: Orforglipron PDUFA. Approval = first oral GLP-1, structural shift for injectable compounding demand. Denial = compounded injectable market gets a reprieve.

Q2 2026: Imapextide (MBX 1416) Phase 2a topline results — GLP-1 receptor antagonist for post-bariatric hypoglycemia. First human data on blocking GLP-1 signaling therapeutically.

Q2 2026: ELI-002 7P Phase 2 primary DFS analysis (KRAS-mutant peptide immunotherapy, pancreatic cancer). Not a biohacking compound — but the most important peptide oncology readout of the year.

Q3 2026: Canvuparatide (MBX 2109) Phase 3 initiation — once-weekly PTH peptide prodrug for hypoparathyroidism, n=~160, EMA Orphan Drug Designation granted. Legitimate precision peptide pipeline with near-term catalysts.

Ongoing: Watch Federal Register daily for any RFK/FDA Category 2 reclassification notice. Every day without a filing makes the "coming weeks" timeline less credible. Also: if you're stacking a GLP-1 with BPC-157 [Anecdotal] or TB-500 [Anecdotal] for body composition, the number to keep in your head is 40-60% — the share of GLP-1 weight loss that is lean mass, not fat. That gap is what your peptide stack is trying to close. There is currently no Phase 2 or Phase 3 data confirming it does.

Data quality note: No fresh Finnrick HPLC results, Janoshik test data, or U.S. compounder pricing confirmed today. Vendor grades reflect last known status — check finnrick.com before ordering. Lilly impurity claim is manufacturer-reported; independent verification of the underlying chemistry has not been published. Recession/inflation decision thresholds are directional heuristics, not hard rules.

Reply to this email with feedback — especially if you're seeing something on r/peptides or Telegram that contradicts what's here.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $5/month.